Code Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $75M

  • Investors
  • 12

Code Bio General Information

Description

Developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases. The company's therapy is leveraging a novel proprietary multivalent synthetic deoxyribonucleic acid delivery platform, 3DNA, that can overcome many of the challenges inherent with viral-based gene therapies, such as immunogenicity, size and delivery limitations, re-disability, and manufacturing complexity, enabling physicians to treat patients with rare and prevalent genetic diseases.

Contact Information

Website
www.codebiotx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 727 Norristown Road, Building 9, 3rd Floor
  • Suite 300
  • Lower Gwynedd, PA 19002
  • United States
+1 (215)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Drug Delivery
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 727 Norristown Road, Building 9, 3rd Floor
  • Suite 300
  • Lower Gwynedd, PA 19002
  • United States
+1 (215)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Code Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 25-May-2022 $75M Completed Clinical Trials - General
2. Seed Round 20-Apr-2021 Completed Clinical Trials - General
1. Accelerator/Incubator Completed Startup
To view Code Bio’s complete valuation and funding history, request access »

Code Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A-2
Series A-1
Seed 1,535,445 $0.000010 8% $6.51 $6.51 1x $6.51 13.01%
To view Code Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Code Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases. The company's the
Drug Discovery
Lower Gwynedd, PA
24 As of 2026

Cambridge, MA
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Code Bio Competitors (3)

One of Code Bio’s 3 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Regenxbio Formerly VC-backed Rockville, MD
Spark Therapeutics Formerly VC-backed Philadelphia, PA
You’re viewing 3 of 3 competitors. Get the full list »

Code Bio Patents

  • 50

    Total Documents Applications and Grants

  • Total Patents Families

  • 23

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

Code Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4757839-A1 Enhanced dna dendrimers and methods of use thereof Pending 09-Aug-2023
WO-2025034978-A1 Enhanced dna dendrimers and methods of use thereof Inactive 09-Aug-2023
AU-2023217717-A1 Enhanced dna dendrimers and methods of use thereof Pending 10-Feb-2022
EP-4475891-A2 Enhanced dna dendrimers and methods of use thereof Pending 10-Feb-2022
EP-4475891-A4 Enhanced dna dendrimers and methods of use thereof Pending 10-Feb-2022 A61K47/6455
To view Code Bio’s complete patent history, request access »

Code Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Code Bio Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amgen Ventures Corporate Venture Capital Minority
Hatteras Venture Partners Venture Capital Minority
Northpond Ventures Venture Capital Minority
UCB Ventures Corporate Venture Capital Minority
4BIO Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Code Bio FAQs

  • When was Code Bio founded?

    Code Bio was founded in 2020.

  • Where is Code Bio headquartered?

    Code Bio is headquartered in Lower Gwynedd, PA.

  • What is the size of Code Bio?

    Code Bio has 24 total employees.

  • What industry is Code Bio in?

    Code Bio’s primary industry is Drug Discovery.

  • Is Code Bio a private or public company?

    Code Bio is a Private company.

  • What is the current valuation of Code Bio?

    The current valuation of Code Bio is .

  • What is Code Bio’s current revenue?

    The current revenue for Code Bio is .

  • How much funding has Code Bio raised over time?

    Code Bio has raised $85M.

  • Who are Code Bio’s investors?

    Amgen Ventures, Hatteras Venture Partners, Northpond Ventures, UCB Ventures, and 4BIO Capital are 5 of 12 investors who have invested in Code Bio.

  • Who are Code Bio’s competitors?

    Intellia Therapeutics, Regenxbio, and Spark Therapeutics are competitors of Code Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process